CUE vs DHR · rev $9.3M vs P/E 39, rev $24.57B
Cue Biopharma (CUE) versus Danaher Corporation (DHR) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Danaher Corporation (DHR) is a diagnostics & research company listed on US.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported DHR revenue for 2025-12-31 was $24.57B. Net income was $3.61B. Revenue was up 2.9% from 2024-12-31 to 2025-12-31. DHR currently screens at market cap $144.18B and trailing P/E 39.0.
CUE currently screens at market cap $59.5M. DHR currently screens at market cap $144.18B and trailing P/E 39.0.
Not investment advice. Open the CUE and DHR stock pages for the full models.
Not investment advice.